2d
GlobalData on MSNTeva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDIâ„¢ for all indications matching the reference ...
Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE ...
Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI â„¢ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara ® (ustekinumab), for the treatment of ...
Alvotech developed and produces SELARSDI using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara®.1 In August ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results